Physician
Urology
Dr. Timothy J. Daskivich, MD
|
|
Give Review
Timothy Daskivich is an expert in the field of Urology. He studied medicine at Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. Timothy J. Daskivich is a published doctor and has 31 publications published. The lastest was: 'The Importance of Accurate Life Expectancy Prediction in Men with Prostate Cancer.' Timothy J. Daskivich, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- The Importance of Accurate Life Expectancy Prediction in Men with Prostate Cancer.
- Re: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer.
- Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link.
- Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
- Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system.
- An Age-Adjusted Comorbidity Index for Prediction of Long-Term, Other-Cause Mortality in Men with Prostate Cancer.
- Prediction of Long-term Other-cause Mortality in Men With Early-stage Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
- Reply to Charlson score and competing mortality.
- Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer.
- Weighted Versus Unweighted Charlson Score to Predict Long-term Other-cause Mortality in Men with Early-stage Prostate Cancer.
- Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
- Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.
- Recurrence of high-risk bladder cancer: A population-based analysis.
- Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
- Comorbidities, Treatment and Survival.
- Improved prediction of long-term, other cause mortality in men with prostate cancer.
- Comorbidities, treatment and ensuing survival in men with prostate cancer.
- Overtreatment of men with low-risk prostate cancer and significant comorbidity.
- Bone scan overuse in staging of prostate cancer: an analysis of a Veterans Affairs cohort.
- Comorbidity and competing risks for mortality in men with prostate cancer.
- Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior...
- Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
- Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4.
- Recent progress in hormonal therapy for advanced prostate cancer.
- Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
- Virilization of a female infant by a maternal adrenocortical carcinoma.
- The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
- Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer.
- From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer.
- Blockade of the CD28/B7 pathway is required for the establishment of donor cell chimerism in CD40 ligand-deficient recipients.
Schools
Harvard Medical School
Doctors Specialties
- Urology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of California PPO
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- Medicare MCR
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
UCLA Medical Center -
Harvard Medical School
Hospital
-
Santa Monica-UCLA Medical Center and Orthopaedic Hospital -
Ronald Reagan UCLA Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225278211 |
| Last Name Of The Provider | DASKIVICH |
| First Name Of The Provider | TIMOTHY |
| View All |
Similar Doctors
|
Dr. Premal J. Desai, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne K. Schuckman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John J. Summers, MD |
|
|
Dr. Howard H. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jean B. Dekernion, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John F. Brasch, MD |
|
|
Dr. Cappy M. Rothman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Thomas L. Johnson, MD |
|
|
Dr. Arthur E. Schapiro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karim Chamie, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|